Data presented at the ASCO Gastrointestinal Cancers Symposium showed the regimen may be a new option, but it comes with more treatment and financial toxicity.
About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of neoadjuvant pembrolizumab, new data revealed.
Bristol Myers Squibb (BMS) has shared promising results from a late-stage study of its dual immunotherapy combination in ...
Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...
Metastatic colorectal cancer with microsatellite instability-high or mismatch repair-deficient status represents a distinct ...
Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...
Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease ...
Dr. Guglietta: Yes. So, it's exactly the challenge. And what we are actually seeing is that at the moment, especially for ...
Researchers at the Francis Crick Institute and Barts Cancer Institute, Queen Mary University of London, have shown that the amount of a protein called CD74 can indicate which people with bowel cancer ...
Cancer immunotherapy drugs, which boost the immune system to fight the tumour, have revolutionised the treatment of the deficient subtype of colorectal cancer. However, these drugs only work in ...
The following is a summary of “Introducing Neoadjuvant Immunotherapy for Colorectal Cancer: Advancing the Frontier,” published in the January 2025 issue of Surgery by Orhan et al. Immunotherapy, ...